CA2685214C - Forme posologique orale a liberation regulee amelioree - Google Patents

Forme posologique orale a liberation regulee amelioree Download PDF

Info

Publication number
CA2685214C
CA2685214C CA2685214A CA2685214A CA2685214C CA 2685214 C CA2685214 C CA 2685214C CA 2685214 A CA2685214 A CA 2685214A CA 2685214 A CA2685214 A CA 2685214A CA 2685214 C CA2685214 C CA 2685214C
Authority
CA
Canada
Prior art keywords
composition
bupropion
cellulose
polymer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2685214A
Other languages
English (en)
Other versions
CA2685214A1 (fr
Inventor
Boyong Li
Chih-Ming Chen
Xiu Xiu Cheng
Avinash Nangia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Priority to CA2796884A priority Critical patent/CA2796884A1/fr
Publication of CA2685214A1 publication Critical patent/CA2685214A1/fr
Application granted granted Critical
Publication of CA2685214C publication Critical patent/CA2685214C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition pharmaceutique conçue pour le dosage quotidien du bupropion, qui comprend (A) une forme à libération soutenue avec (i) une base de bupropion ou d'un sel acceptable du point de vue pharmaceutique ou un stéréoisomère de celui-ci et (ii) un composé à libération soutenue et (B) une forme à libération immédiate du bupropion ou d'un sel acceptable du point de vue pharmaceutique ou un stéréoisomère de celui-ci.
CA2685214A 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree Expired - Fee Related CA2685214C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2796884A CA2796884A1 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26745601P 2001-02-08 2001-02-08
US26745701P 2001-02-08 2001-02-08
US60/267,456 2001-02-08
US60/267,457 2001-02-08
CA2433915A CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2433915A Division CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2796884A Division CA2796884A1 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Publications (2)

Publication Number Publication Date
CA2685214A1 CA2685214A1 (fr) 2002-08-15
CA2685214C true CA2685214C (fr) 2013-01-22

Family

ID=26952450

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2685214A Expired - Fee Related CA2685214C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree
CA2433915A Expired - Fee Related CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree
CA2796884A Abandoned CA2796884A1 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2433915A Expired - Fee Related CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree
CA2796884A Abandoned CA2796884A1 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Country Status (3)

Country Link
EP (1) EP1357898A4 (fr)
CA (3) CA2685214C (fr)
WO (1) WO2002062299A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
CA2601800C (fr) * 2005-03-14 2013-12-03 Nitin Bhalachandra Dharmadhikari Systeme d'administration de medicament par voie orale
US8394415B2 (en) 2006-11-21 2013-03-12 Mcneil-Ppc, Inc Modified release analgesic suspensions
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US8956654B2 (en) 2009-06-02 2015-02-17 Dow Global Technologies Llc Sustained release dosage form
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331906T2 (de) * 1992-08-05 2002-12-19 Faulding F H & Co Ltd Granulierte pharmazeutische zusammensetzung
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Also Published As

Publication number Publication date
EP1357898A4 (fr) 2005-07-13
CA2685214A1 (fr) 2002-08-15
CA2433915A1 (fr) 2002-08-15
WO2002062299A3 (fr) 2003-04-24
CA2433915C (fr) 2010-04-20
CA2796884A1 (fr) 2002-08-15
EP1357898A2 (fr) 2003-11-05
WO2002062299A2 (fr) 2002-08-15

Similar Documents

Publication Publication Date Title
US7771750B2 (en) Controlled release oral dosage form
US6589553B2 (en) Controlled release oral dosage form
JP2637981B2 (ja) 吸収制御薬剤組成物
CA2686094A1 (fr) Methode de fabrication d'un element semiconducteur
EP1879556B1 (fr) Systemes de liberation chronocontrolee par impulsions
AU2002330211B2 (en) Timed, sustained release multi-particulate dosage forms of propranolol
AU757915B2 (en) Controlled release bupropion formulation
JPH0476966B2 (fr)
CZ296964B6 (cs) Farmaceutické formulace tramadolu v násobných jednotkách a zpusob jejich výroby
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
KR20080007252A (ko) 양성 전립선 과다형성증용 치료 조합물
HUE029680T2 (en) Dispensing systems containing weakly basic active ingredients and organic acids
JP2001507359A (ja) 徐放性シサプリドミニ錠剤製剤
US10213389B2 (en) Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
EP1711169B1 (fr) Minicomprimes revetus a liberation prolongee de chlorhydrate de venlafaxine
US20030035840A1 (en) Controlled release oral dosage form
CA2685214C (fr) Forme posologique orale a liberation regulee amelioree
EP3630074A1 (fr) Forme posologique orale multiparticulaire permettant une libération prolongée de tapentadol
AU2013217013B2 (en) Modified release formulations of viloxazine
US20090297602A1 (en) Modified Release Loxoprofen Compositions
AU2002253907A1 (en) Improved controlled release oral dosage form
JP2005510449A (ja) 改良型制御放出経口剤形
AU2013273835B2 (en) Timed, pulsatile release systems

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200210